Literature DB >> 22543254

Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients.

M Kosmalski1, A Drozdowska, A Sliwinska, J Drzewoski.   

Abstract

PURPOSE: Metformin is the most commonly prescribed anti-diabetic medication. However, it is often used despite the presence of contraindications and in unlicensed indications. The main aim of this study was to evaluate the frequency of metformin use before hospitalization in spite of contraindications in patients with type 2 diabetes mellitus (T2DM) and to evaluate the prevalence of metformin - associated side effects. MATERIAL/
METHODS: 558 hospitalized patients (mean age = 66.65 ± 12.73 years) with poorly controlled T2DM were enrolled. Detailed medical history including the duration of T2DM, duration of hypoglycemic agents usage prior to hospitalization and possible metformin-associated side effects was recorded. Patients were subjected to a thorough physical examination and indispensable biochemical and diagnostic research panel was performed to establish the degree of heart failure, sufficiency of the respiratory system and kidney function.
RESULTS: 335 out of 558 patients were treated before hospitalization with metformin alone or in combination with other hypoglycemic agents, mostly sulfonylureas. Contraindications to metformin were found in 275 patients and despite this 120 of them were using this medication in an average dose of 1793.91 ± 701.61 mg. However, none of them reported any serious adverse effects and no significant pH changes were observed. Only three patients reported moderate dyspepsia.
CONCLUSIONS: The results of this study indicate a relatively good tolerability of metformin by patients with the traditional contraindications to this drug. These findings support other authors' suggestion that indications and contraindications to metformin should be re-evaluated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543254     DOI: 10.2478/v10039-012-0017-7

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  7 in total

1.  Fatal metformin overdose: case report and postmortem biochemistry contribution.

Authors:  Alessandro Bonsignore; Fulvia Pozzi; Giulio Fraternali Orcioni; Francesco Ventura; Cristian Palmiere
Journal:  Int J Legal Med       Date:  2013-11-08       Impact factor: 2.686

Review 2.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Authors:  Silvio E Inzucchi; Kasia J Lipska; Helen Mayo; Clifford J Bailey; Darren K McGuire
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

Review 3.  Cardiovascular safety profile of currently available diabetic drugs.

Authors:  Komola Azimova; Zinnia San Juan; Debabrata Mukherjee
Journal:  Ochsner J       Date:  2014

Review 4.  The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.

Authors:  Józef Drzewoski; Markolf Hanefeld
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-05

5.  Metformin initiation and renal impairment: a cohort study in Denmark and the UK.

Authors:  Christian Fynbo Christiansen; Vera Ehrenstein; Uffe Heide-Jørgensen; Stine Skovbo; Helene Nørrelund; Henrik Toft Sørensen; Lin Li; Susan Jick
Journal:  BMJ Open       Date:  2015-09-02       Impact factor: 2.692

6.  Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients.

Authors:  Carlos E Mendez; Guillermo E Umpierrez
Journal:  Diabetes Spectr       Date:  2014-08

7.  Prevalence of Metformin Use and the Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: A National Cross-Sectional Study.

Authors:  Chin-Chi Kuo; Hung-Chieh Yeh; Bradley Chen; Ching-Wei Tsai; Yu-Sheng Lin; Chiu-Ching Huang
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.